Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$95.7K Hold
790
0.08% 74
2025
Q4
$83.8K Hold
790
0.07% 79
2025
Q3
$66.9K Hold
790
0.05% 91
2025
Q2
$63.2K Sell
790
-123
-13% -$9.78K 0.05% 93
2025
Q1
$93.3K Sell
913
-518
-36% -$48.4K 0.09% 78
2024
Q4
$143K Sell
1,431
-18
-1% -$1.86K 0.12% 68
2024
Q3
$166K Hold
1,449
0.15% 64
2024
Q2
$180K Hold
1,449
0.18% 59
2024
Q1
$192K Sell
1,449
-640
-31% -$78.9K 0.18% 52
2023
Q4
$229K Buy
+2,089
New +$217K 0.22% 44

Other funds holding MRK

Fairman Group's MRK Position: Q1 2026 in Review

Fairman Group held its Merck (MRK) position steady in Q1 2026 at 790 shares worth $95.7K. The position accounts for 0.08% of the portfolio, ranked #74.

Fairman Group first reported a position in MRK in Q4 2023 and has held it in 10 quarters since. The position peaked at $229K in Q4 2023. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Fairman Group held 790 shares of Merck worth $95.7K as of Q1 2026.
  • Fairman Group left its Merck share count unchanged in Q1 2026.
  • Merck made up 0.08% of Fairman Group's portfolio in Q1 2026, its #74 holding.
  • Fairman Group first reported a position in Merck in Q4 2023 and has held it in 10 quarters since.
  • Fairman Group's Merck position peaked at $229K in Q4 2023.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Fairman Group's 13F filing for Q1 2026, filed 23 Apr 2026.